北米の心臓弁デバイス市場 – 業界動向と2030年までの予測

北米心臓弁デバイス市場の分析と洞察

心臓弁デバイスは閉塞した心臓弁を治療するために使用され、これらのデバイスの移植は最も一般的な手順の1つです。市場で入手可能な構造的心臓弁デバイスには、機械弁、生物学的弁、および経カテーテル弁が含まれます。北米の心臓弁デバイス市場は、世界中で心臓弁手術の数が増加しているため、予測期間中に着実に成長する可能性があります。北米の心臓弁デバイス市場の成長は、大動脈弁、左心房閉塞デバイス、組織弁または生物学的弁などの構造的心臓デバイスと手順の開発によって推進されると予想されます。組織弁はすでに心臓弁デバイス市場に革命をもたらしました。次世代の心臓弁手術は、低出産患者プロファイル、より制御された手術、より優れた弁機能、弁周囲逆流の減少、耐久性の向上、および低コストを提供します。主要な市場プレーヤーによる製品革新により、より多くの患者層に対応し、より良い臨床結果を達成できるようになり、市場の成長が促進されました。

Data Bridge Market Research の分析によると、心臓弁デバイス市場は予測期間中に 13.6% の CAGR で成長し、2030 年までに 105 億 7,902 万米ドルに達する見込みです。世界中で心臓弁デバイスの需要が急増しているため、製品タイプが市場で最大のセグメントを占めています。この市場レポートでは、価格分析、特許分析、技術進歩についても詳細に取り上げています。

心臓弁デバイス市場の定義

Heart valves are necessary to smooth blood movement in the right direction in the body. Heart valves are responsible for constant blood flow, and maintaining blood pressure. If they don't work properly cutting off the heart causes stenosis. Heart disease generally includes several diseases that significantly affect the heart. The regulation of heart valves has increased rapidly in the last ten years as the number of patients suffering from cardiovascular diseases has increased. The market growth of heart valves is accelerated by factors such as unstable lifestyles, lifestyle diseases, increasing smoking population, aging population, and increasing quality of healthcare, and rapid development of healthcare reimbursement during the forecast period. In addition, the high cost of heart valves and the risk of infection of heart implants may be the reason that is likely to slow down the growth of the heart valve market during the above-mentioned forecast period. Growth in medical business aspects and groundwork in emerging economies is fueling growth in medical tourism, driving the heart valve device market. The need for minimally invasive procedures to treat cardiac abnormalities has greatly increased. Current applications of automation in heart valve surgery, such as Transcatheter Aortic Valve Replacement (TAVR), have given way to a growing variety of similar surgeries. Judging by the increasing proportion of the aging population, the increase in life insurance policies is also expected to contribute to the growth of the heart valve market.

 Heart Valve Devices Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:    

Drivers

• Innovations in Heart Valve Devices Offer Improved Clinical Outcome

Launching new products for minimally invasive procedures will likely drive the North America heart valve devices market. Tissue valves have revolutionized the heart valve market. The next generation of heart valve surgery offers fewer delivery curves, more controlled placement, improved valve function, reduced valve regurgitation, increased durability, and reduced cost. Product innovation has boosted the growth prospects of heart valve device market players as it can treat a larger number of patients with superior clinical outcomes. Despite significant advances in recent years, structural interventional cardiology remains an emerging market with great potential.

Moreover, intelligent designs, new technologies, and biomaterials applications continue to push the boundaries of new product development, ensuring that these devices will be at the forefront of interventional product innovation for years to come. Design innovations are helping market players tap profitable growth opportunities in heart valve devices.

Thus, the growth of the North America heart valve devices market is expected to propel due to the rise in innovations in heart valve devices.

• Rising number of various heart diseases

Heart attacks and strokes are usually acute events and are primarily caused by a blockage that blocks blood flow to the heart or brain. During the first year of the COVID-19 pandemic, heart disease and stroke deaths increased by 5.8% and 6.8%, respectively. However, the age-associated increases were 1.6% and 1.7% for heart disease and stroke, respectively. The most common cause is the build-up of fatty deposits in the lining of the blood vessels that supply the heart or brain. A stroke can be caused by bleeding or blood clots in a blood vessel in the brain. This trend suggests that the incidence of cardiovascular disease may increase dramatically due to population growth and aging.

Furthermore, High diabetes and blood pressure, high blood cholesterol, and smoking are key risk factors for heart disease. About half of people in the United States (47%) have at least one of these three risk factors. Other medical conditions and lifestyle choices can also put people at a higher risk for heart disease, including unhealthy diet, physical inactivity, and excessive alcohol use.

Moreover, the rising number of heart diseases is expected to act as a driver for the North America heart valve devices market.

Opportunity

• Increasing Awareness of Prosthetic Devices

A prosthesis is a device designed to replace a missing body part or to improve the function of a body part. Prosthetic heart valves are increasingly used in cases of abnormalities of the natural valves that require intervention. Generally, they can be divided into mechanical heart valves, biological valves, and allogeneic grafts. The goal of artificial valves is to act hemodynamically like a natural valve with minimal side effects. Cardiovascular prostheses devices have been developed to replace damaged heart tissue. These medical devices are designed to mimic the function of normal cardiovascular organs. Artificial hearts allow heart surgeons to increase the treatment of heart blocks.

Moreover, the prevalence of prosthetic valves ranges from 0.2 per 1,000 in people years of age or younger to 5.3 in people years of age or younger.

Thus the increasing awareness about prosthetic devices acts as an opportunity for the market's growth.

Restraint/Challenge

• Expensive Production Cost of Equipment

The number of patients treated for aortic valve disease in the United States is growing quickly. Transcatheter aortic valve replacement (TAVR) replaces surgical aortic valve replacement (SAVR) and medical treatment (M.T.). The economic consequences of these trends are unknown. Therefore, the total cost of TAVR is higher than SAVR and much more expensive than M.T. alone. TAVR costs have decreased over time, while SAVR and M.T. costs have remained the same.

In addition, the high surgical cost of TAVI is mainly due to the high cost of the production. However, due to the shorter hospital stay, the cost of non-surgical TAVI is lower compared to AVR. The cost of the TAVI implant kit alone (valve, balloon, sheath) is $32,500, while the surgical valve only costs about $5,000, just like in Switzerland, the TAVI implant set costs about 32,000 francs (around of $35,000), while the cost of a biosurgical prosthesis is about 3,000 Swiss francs (about US$3,300). Depending on comorbidities and complications, reimbursement in the United States is between $ 0,000 and $ 5,000, TAVI in Switzerland is about 72,000 francs ($78,000), and AVR is about 3,000 francs ($ 7,000), which means a financial loss for the hospital.

Thus, the rising production cost of equipment may hamper the market's growth.

Recent Developments

• In September 2023, Abbott released data from five late-stage presentations showing the benefits of its minimally invasive devices in treating people with various structural heart diseases. The data includes findings that support the value of MitraClip™. It is the world's first and leading transcatheter edge-to-edge repair (TEER) to treat leaky valves in people with mitral regurgitation (MR). New data on Abbott's structural heart therapies were presented at the Cardiovascular Research Foundation's 34th Annual Transcatheter Cardiovascular Therapy (TCT) Scientific Symposium in Boston. This has helped the company to increase its business position in the market.
• In September 2020, Boston Scientific Corporation announced that it had introduced a controlled launch of the ACURATE neo2™ aortic valve system in Europe. This next-generation transcatheter aortic valve implantation (TAVI) technology is a new platform designed with multiple features to improve the clinical performance of the original ACURATE new platform. Compared to the previous generation, the ACURATE neo2 valve system has an expanded indication for patients with aortic stenosis. This has helped the company to gain its product portfolio.

Heart Valve Devices Market Scope

The heart valve devices market is segmented into product type, treatment, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

BY PRODUCT TYPE

• Mechanical Heart Valves
• Biological Heart Valve
• Transcatheter Valves

On the basis of product type, the heart valve devices market is segmented into mechanical heart valve, biological heart valve and transcatheter valve.

BY TREATMENT

• OPEN SURGERY
• MINIMALLY INVASIVE SURGERY

On the basis of treatment, the heart valve devices market is segmented into open surgery and minimal invasive surgery.

 BY END USER

• HOSPITAL & CLINICS
•  AMBULATORY SURGICAL CENTERS
• CARDIAC CENTERS
• RESEARCH CENTERS
• OTHERS

エンドユーザーに基づいて、心臓弁装置市場は、病院と診療所、外来手術センター、心臓センター、研究センターなどに分類されます。

流通チャネル別

• 直接入札
• サードパーティディストリビューター

流通チャネルに基づいて、心臓弁デバイス市場は、直接入札とサードパーティの販売代理店に分類されます。

北米心臓弁デバイス市場地域分析/洞察

心臓弁装置市場が分析され、製品タイプ、治療、エンドユーザー、流通チャネルに関する市場規模の情報が提供されます。

この市場レポートでカバーされている国は、米国、カナダ、メキシコです。

北米は、研究開発への投資の増加により、市場を支配しています。主要企業の強力な存在により、米国は北米地域を支配しています。

レポートの国別セクションでは、市場の現在および将来の傾向に影響を与える国内市場における個別の市場影響要因と規制の変更も提供しています。新規販売、交換販売、国の人口統計、規制行為、輸出入関税などのデータ ポイントは、各国の市場シナリオを予測するために使用される主要な指標の一部です。また、国別データの予測分析を提供する際には、北米ブランドの存在と可用性、地元および国内ブランドとの競争が激しいか少ないために直面​​する課題、販売チャネルの影響も考慮されます。

競争環境と心臓弁デバイス市場シェア分析

心臓弁装置市場の競争状況は、競合他社ごとに詳細を提供します。含まれる詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、生産拠点と施設、会社の強みと弱み、製品の発売、製品試験パイプライン、製品の承認、特許、製品の幅と幅、アプリケーションの優位性、技術ライフライン曲線などがあります。提供されている上記のデータ ポイントは、心臓弁装置市場に対する会社の重点にのみ関連しています。

心臓弁デバイス市場で活動している主要企業としては、Abbott、Boston Scientific Corporation またはその関連会社、Artivion, Inc.、Edwards Lifesciences Corporation、Medtronic、NeoVasc、Micro Interventional Devices Incorporated、XELTIS、TTK、Meril Life Sciences Pvt. Ltd、Foldax, Inc.、Venus Medtech (Hangzhou) Inc.、Colibri Heart Valve などが挙げられます。

SKU-69459